Early Approval = Better Reimbursement IDE Coverage Can Be Critical for Sites

Discover why research sites should view early CMS approval as a critical part of their investigational device exemption (IDE).

CMS notifications and billing processes can be a hassle, which is why many studies prefer to participate in sponsor-funded trials. Unfortunately, this trend ignores the significant payoffs enjoyed when CMS approval is actively pursued from the beginning. Medicare-approved MedTech studies enjoy a number of short-term and long-term benefits, such as the earliest possible cost savings to the patient as well as proactive CMS data collection for future reimbursement strategies.

Review our fact sheet on the realities and rewards of CMS approval, then decide if you need to seek guidance on the best course for your IDE.

Download Fact Sheet

Back to Resources